Welcome to our dedicated page for Editas Medicine news (Ticker: EDIT), a resource for investors and traders seeking the latest updates and insights on Editas Medicine stock.
Editas Medicine, Inc. (Nasdaq: EDIT) is a clinical-stage gene editing company that regularly issues news and updates about its in vivo CRISPR-based pipeline. Company announcements emphasize the development of transformative in vivo medicines using CRISPR/Cas12a and CRISPR/Cas9 systems, proprietary targeted lipid nanoparticle delivery, and a differentiated gene upregulation strategy applied to serious diseases.
News about Editas Medicine frequently covers progress with its lead in vivo development candidate, EDIT-401, an LDLR-targeted gene editing medicine designed to treat hyperlipidemia by increasing LDL receptor expression and reducing LDL cholesterol (LDL-C) levels. Recent releases have described preclinical proof-of-concept data in non-human primates and mice, showing approximately 90% or greater reductions in LDL-C after a single dose, as well as presentations at major scientific meetings such as the European Society of Gene and Cell Therapy Congress and the American Heart Association Scientific Sessions.
Investors and followers of EDIT can also expect updates on Editas’ in vivo hematopoietic stem cell program for sickle cell disease and beta thalassemia, including data on HBG1/2 promoter editing, fetal hemoglobin upregulation, and targeted lipid nanoparticle delivery in humanized mice and non-human primates. Additional news items highlight in vivo proof-of-concept for undisclosed liver targets, conference presentations at ASGCT, EHA, and TIDES, and participation in healthcare and investor conferences.
Financial news from Editas Medicine includes quarterly results, collaboration milestones such as the CD19 HD allogeneic CAR T program with Bristol Myers Squibb, and updates on cash runway supported by cash, marketable securities, at-the-market equity proceeds, and payments under its license agreement with Vertex Pharmaceuticals. This news page helps readers follow how scientific data, regulatory plans, collaborations, and financial developments shape the EDIT investment story over time.
Editas Medicine has unveiled promising preclinical data on engineered induced pluripotent stem cell (iPSC)-derived natural killer (NK) cells, showcasing enhanced anti-tumor properties through the CRISPR/Cas12a-mediated SLEEK technology. This technology allows for efficient knock-in of CD16 and IL-15 genes, significantly improving NK cell persistence and serial tumor cell killing capabilities. Results presented at the SITC Annual Meeting indicated that these modifications could lead to safer, off-the-shelf immunotherapy options targeting solid tumors.
Editas Medicine reported promising results from its EDIT-101 Phase 1/2 BRILLIANCE trial, showcasing a favorable safety profile and signals of clinical benefit in treating Leber Congenital Amaurosis 10 (LCA10). The company is continuing patient enrollment in both adult high-dose and pediatric mid-dose cohorts. Additionally, the ongoing EDIT-301 Phase 1/2 RUBY trial for sickle cell disease is also enrolling participants. Strong financial backing was reported with $657 million in cash as of September 30, 2021, despite a net loss of $39.1 million during Q3.
Editas Medicine (Nasdaq: EDIT) announced that two scientific abstracts featuring preclinical data will be presented at the 63rd Annual Meeting of the American Society of Hematology (ASH) from December 11-14, 2021. The data highlights the potential of EDIT-301, an autologous cell therapy for transfusion-dependent beta thalassemia (TDT), demonstrating improved red blood cell production. Additionally, engineered iNK cells displayed enhanced tumor reduction capabilities. Editas aims to file an IND by year-end, emphasizing the promise of its CRISPR technology in treating serious diseases.
Editas Medicine (Nasdaq: EDIT) has appointed Bernadette Connaughton to its Board of Directors. With over 30 years of experience in the pharmaceutical sector, Connaughton has a proven history of driving sales growth and profitability, notably at Bristol-Myers Squibb. Her expertise in global commercialization and product launches is expected to strengthen Editas' mission to develop innovative genomic medicines. This leadership change aims to enhance the company's pipeline and operational strategy as it advances treatments for serious diseases.
Editas Medicine, a leader in genome editing, will host a conference call on November 8, 2021, at 8:00 a.m. ET. The call will provide a corporate update and third-quarter results for 2021. U.S. participants can join by calling 877-407-0989, while international callers can dial 201-389-0921. A live webcast will also be available on the Editas Medicine website. Editas focuses on developing CRISPR/Cas9 and CRISPR/Cas12a technologies to create precise genomic medicines for serious diseases globally.
Editas Medicine announced that initial clinical data from the BRILLIANCE trial of EDIT-101 will be presented at the ESGCT Annual Congress, held virtually from October 19-22, 2021. EDIT-101 targets Leber congenital amaurosis 10 (LCA10), a retinal degenerative disorder associated with CEP290. Early efficacy signals from the mid-dose cohort indicate positive biological activity and a favorable safety profile. The BRILLIANCE trial assesses the safety, tolerability, and efficacy of EDIT-101, enrolling up to 18 patients across multiple dose levels.
Editas Medicine, Inc. (Nasdaq: EDIT) announced its presentation of preclinical data on cell therapy for cancer treatment at the SITC 36th Annual Meeting held from November 10-14, 2021. The data showcases a new method for high-level CD16 expression in iPSC-derived natural killer cells, demonstrating enhanced cytotoxic activity against tumor cells. The poster presentation is scheduled for November 12, 2021. Editas focuses on developing transformative genomic medicines using CRISPR technology to address serious diseases.
Editas Medicine will present at Chardan’s 5th Annual Genetic Medicines Conference on October 4, 2021, at 8:30 a.m. ET. Attendees can access a live webcast through the Investors section of the Editas Medicine website, with an archived replay available for 30 days post-event.
Editas Medicine focuses on delivering transformative genomic medicines utilizing CRISPR technology to treat serious diseases globally. For more details, visit www.editasmedicine.com.
Editas Medicine has released positive initial clinical data from the ongoing Phase 1/2 BRILLIANCE trial of EDIT-101, an experimental treatment for blindness due to Leber congenital amaurosis 10 (LCA10).
Notable findings include a favorable safety profile observed over 15 months with no serious adverse events and signs of efficacy in the mid-dose cohort, showing visual improvements and successful gene editing.
The trial continues with adult high-dose and pediatric mid-dose cohorts, offering hope for patients with this rare genetic disorder.
Editas Medicine (NASDAQ: EDIT) announced the appointment of Emma Reeve to its Board of Directors. With over 25 years of experience in the biopharmaceutical sector, Reeve brings a strong financial background, previously serving as CFO at Constellation Pharmaceuticals and holding senior roles at major firms like Bristol-Myers Squibb and Merck. Reeve’s addition aims to enhance Editas's operational effectiveness and fundraising capabilities as the company continues advancing its pipeline and technologies for genome editing.